SCHEMBL20161614

SCHEMBL20161614

CN1CCN(C)[C@H](C#N)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23556321 1.00
SCHEMBL16122262 1.00
SCHEMBL15722725 0.98 DPP4 (0.30)
SCHEMBL11148793 0.79
SCHEMBL22249208 0.76
SCHEMBL20326314 0.74 DRD2 (0.31)
SCHEMBL22880761 0.74 DPP4 (0.31)
SCHEMBL21794727 0.74
SCHEMBL15432298 0.71 CYP1A2 (0.38)
SCHEMBL20326344 0.70 JAK3 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022265974-A1 AMINOHETEROCYCLE-SUBSTITUTED TRICYCLIC KRAS INHIBITORS ERASCA, INC. (US) 2022-12-22 WO disclosed
WO-2022266167-A1 AMIDE AND UREA-CONTAINING TRICYCLIC KRAS INHIBITORS ERASCA, INC. (US) 2022-12-22 WO disclosed
EP-3534899-B1 COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE CORVUS PHARMACEUTICALS INC (US) 2022-06-01 EP disclosed
WO-2021127404-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES ERASCA, INC. (US) 2021-06-24 WO disclosed
WO-2018089261-A2 COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE CORVUS PHARMACEUTICALS, INC. (US) 2018-05-17 WO disclosed